Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Global impact and cost-effectiveness of tuberculosis interventions.
HORTON, KC; SCHWALB, A; HARKER, MJ; Goscé, L; Venero-Garcia, E; O'Brien, L; Gun, A; SUMNER, T; MCQUAID, CF; Clark, RA; Prys-Jones, TO; Bakker, R; Liu, YE; Kubjane, M; Lienhardt, C; White, RG; HOUBEN, RM G J;
2026
Nature Health (2026). 10.1038/s44360-026-00171-5.
Once-Daily Dolutegravir-Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for Treatment of Cryptococcal Meningitis: Results of a ...
ELLIS, J; HALE, G; Buzibye, A; Omali, D; Naluyima, S; Ntenkaire, N; Nsangi, LJ; Ndyetukira, JF; Sadiq, A; Ahimbisibwe, C; Nabbaale, S; Tukundane, A; Bakka, W; Gakuru, J; Kawuma, AN; Cresswell, FV; MOORE, DA J; Meya, DB; Boulware, DR; Waitt, C; JARVIS, JN; Nicol, MR;
2026
Open forum infectious diseases, (2026).13 8 10.1093/ofid/ofag415.
How can new TB vaccines be effectively introduced in Indonesia? Insights from diverse stakeholders.
Putri, ND; Fuady, A; Soeharno, N; Zafira, AS; Valeria, MS; Wicaksana, P; Yuniar, P; Nadjib, M; Yudha, A; THOMAS, KA; CLARK, RA; Hadinegoro, SR; WHITE, RG;
2026
PLOS global public health, (2026).6 7 10.1371/journal.pgph.0005537.
Context matters: WHO-recommended tools in combinations validated for community tuberculosis screening.
KHAN, P; KRANZER, K;
2026
The Lancet. Infectious diseases (2026). 10.1016/s1473-3099(26)00234-3.
Association of Diabetes Mellitus With a Shared Hyperinflammatory Immune Response in Patients With Melioidosis and Patients With Tuberculosis: An Observational Case-Control Study.
Rongkard, P; Kronsteiner, B; Eckold, C; Chamnan, P; Chumseng, S; Ali, M; Hill, J; Abraham, P; Marchi, E; Limmathurotsakul, D; Chantratita, N; West, TE; Gharib, SA; CLIFF, JM; Day, NP J; Klenerman, P; Dunachie, SJ;
2026
Open Forum Infect Dis, (2026).13 6 10.1093/ofid/ofag286.
What is the feasibility and acceptability of stool sampling and testing for childhood tuberculosis diagnosis? A qualitative study in The Gambia.
OWUSU, SA; EDEM, VF; NKEREUWEM, E; Danso, M; Boakarie, M; Koita, SW; Kandeh, S; Jallow, M; Baldeh, T; Gomez, M; BUSZA, J; TOGUN, TO;
2026
BMJ open, (2026).16 6 10.1136/bmjopen-2025-114409.
People with prior tuberculosis have accelerated frailty and differential survival into older age: a cross-sectional analysis in Southern Africa.
Coleman, M; Manyara, A; Calderwood, CJ; De Wilton, A; Madela, EI Y; Wilson, H; Burton, A; Gates, L; Cassim, B; Pearse, C; Madanhire, T; FERRAND, RA; Ward, KA; KRANZER, K; Gregson, CL;
2026
The Journal of infectious diseases (2026). 10.1093/infdis/jiag299.
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation.
Romo, M; LaHood, A; Mitnick, CD; Rich, ML; Trevisi, L; Skrahina, A; Oyewusi, L; Bastard, M; KHAN, PY; Huerga, H; Khan, U; Herrera Flores, E; Atshemyan, H; Hewison, C; Rashitov, M; Samieva, N; Gómez-Restrepo, C; Krisnanda, A; Kotrikadze, T; Siraj, F; Khan, AW; Ndjeka, N; Adenov, M; Seung, KJ; Kumsa, A; ... Franke, MF.
2026
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). 10.1093/cid/ciag361.
The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design.
Dagnew, AF; Schmidt, AC; Cinar, A; Garcia-Basteiro, AL; Noble, R; Pelzer, PT; Churchyard, GJ; Hatherill, M; WHITE, RG; Cobelens, F;
2026
Vaccine, (2026).88, 10.1016/j.vaccine.2026.128822.
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.
Nyang'wa, B-T; Motta, I; Moodliar, R; Solodovnikova, V; Rajaram, S; Rasool, M; Berry, C; MOORE, DA J; Davies, G; Kloprogge, F;
2026
Nature communications, (2026).17, 10.1038/s41467-026-74335-y.